SARS-CoV-2, the virus that causes COVID-19, can be detected by methods such as Real-Time Reverse Transcriptase (RT)-PCR. Only laboratories capable of high complexity testing and certified under the Clinical Laboratory Improvement Amendments (CLIA) are able to perform this test. We can translate the data exported from your RT-PCR instrument directly into a report that shows clinicians if the target for COVID-19 has been detected. This testing methodology is developed by the CDC and can be approved under an Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA). We can help certify testing that continuously meets the guidelines set forth by the CDC as well as the FDA.
The CDC has also developed a serology test used to help estimate how many people have been previously infected with SARS-CoV-2. This testing method detects the presence or absence of proteins made in response to an infection. These specific proteins, also known as antibodies, can be detected in the blood of someone previously positive for COVID-19.
During this unprecedented time, it is essential that those involved in the public health industry work together to find a solution to help those in need. The demand for more laboratories to perform COVID-19 testing has grown enormously with over 10 million cases confirmed around the world. We work hand-in-hand with laboratories that manage a rapid influx of COVID-19 samples by providing a program that maximizes both testing and reporting capabilities. Time-sensitive information can be consolidated into a predetermined format, allowing ease of reporting positive samples to state public health laboratories. Our interface can be customized to connect laboratories with required epidemiological reporting facilities. We also provide customer support that is available 24/7 to assist with your laboratory needs.
To all workers on the front lines providing care to patients and protecting our community during this pandemic, we thank you!